Press Releases

Press Releases

Date Title and Summary Additional Formats
Sep 25, 2019 Catalyst Pharmaceuticals to Participate in the 2019 Cantor Global Healthcare Conference
CORAL GABLES, Fla. , Sept. 25, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Sep 23, 2019 Catalyst Pharmaceuticals, Inc. Comments on Trading in its Common Stock and on its Capital Resources
CORAL GABLES, Fla. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) is commenting on today's trading activity in its common stock and on the current state of its capital resources. The Company is reporting that it is not aware of any information about the
Sep 13, 2019 Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
CORAL GABLES, Fla. , Sept. 13, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc.  (NasdaqCM: CPRX) today announced that it will not conclude the offering of shares of its common stock announced on Wednesday, September 11, 2019 . The Company believes that the culmination of an offering at the
Sep 11, 2019 Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
CORAL GABLES, Fla. , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) announced today that it has commenced an underwritten public offering of 8.0 million shares of its common stock. Catalyst also intends to grant the underwriters a 30-day option to purchase up to
Aug 28, 2019 Catalyst Pharmaceuticals to Participate in the 14th Annual Citi Biotech Conference on September 4th, 2019
CORAL GABLES, Fla. , Aug. 28, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Aug 07, 2019 Catalyst Pharmaceuticals Announces Second Quarter 2019 Financial Results and Provides Corporate Update
Firdapse ® Launch Momentum Continues with Second Quarter Net Revenues of $28.8 Million 409 Adult LEMS Patients Active on Firdapse as of June 30, 2019 Company to Host Quarterly Conference Call at 8:30 am ET Tomorrow CORAL GABLES, Fla. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals,
Aug 01, 2019 Catalyst Pharmaceuticals Announces Its Support of Spinal Muscular Atrophy Awareness Month
CORAL GABLES, Fla. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Jul 31, 2019 Catalyst Pharmaceuticals to Hold Second Quarter 2019 Financial Results Conference Call and Webcast on Thursday, August 8th, 2019
CORAL GABLES, Fla. , July 31, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today
Jun 12, 2019 Catalyst Pharmaceuticals Files Federal Lawsuit Against U.S. Food and Drug Administration
Complaint Cites Multiple Violations of Food, Drug, and Cosmetic Act CORAL GABLES, Fla. , June 12, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), today announced it has filed a suit against the U.S. Food and Drug Administration ( FDA ) and several related parties
Jun 04, 2019 Catalyst Pharmaceuticals to Present at the Jefferies 2019 Global Healthcare Conference
CORAL GABLES, Fla. , June 04, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today

Displaying 1 - 10 of 20